[{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Olaratumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Telix Pharmaceuticals \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Telix Pharmaceuticals \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Olaratumab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eli Lilly \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Telix Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals for Olaratumab

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : LY3012207 (olaratumab) is a mAb targeting PDGFRα. It was granted accelerated approval in the U.S. and conditional approval in the EU based on Phase II trial data which showed a 1-year survival benefit in patients with STS, when given in combination with...

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          April 17, 2023

                          Lead Product(s) : Olaratumab,Doxorubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Telix Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : The exclusive worldwide licence will allow Telix to repurpose LY3012207 (olaratumab) as a targeting agent for radiopharmaceutical imaging and therapy of cancer.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : $5.0 million

                          October 04, 2022

                          Lead Product(s) : Olaratumab,Doxorubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Eli Lilly

                          Deal Size : $230.0 million

                          Deal Type : Licensing Agreement

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          June 21, 2019

                          Lead Product(s) : Olaratumab,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          University of Miami

                          Country arrow
                          EPSC
                          Not Confirmed

                          University of Miami

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 19, 2018

                          Lead Product(s) : Trabectedin,Doxorubicin Hydrochloride,Olaratumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Johnson & Johnson Innovative Medicine

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          September 14, 2017

                          Lead Product(s) : Olaratumab,Doxorubicin Hydrochloride,Ifosfamide,Mesna

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          April 24, 2017

                          Lead Product(s) : Olaratumab,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Merck & Co

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          March 22, 2017

                          Lead Product(s) : Olaratumab,Paclitaxel,Gemcitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          February 17, 2017

                          Lead Product(s) : Doxorubicin Hydrochloride,Docetaxel,Gemcitabine,Polyferon,Pembrolizumab,Ipilimumab,Interferon Alpha-2b,Bortezomib,Aldesleukin,Trabectedin,Eribulin,Olaratumab,Atezolizumab,Durvalumab,Aveluma,Nivolumab,Larotrectinib,Entrectinib,Avapritinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Fred Hutchinson Cancer Center | University of Washington | Northwell Health | Oregon Health and Science University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          May 26, 2016

                          Lead Product(s) : Olaratumab,Doxorubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          February 09, 2016

                          Lead Product(s) : Olaratumab,Doxorubicin Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank